Skip to main content

Table 3 Characteristics of patients who did not achieve rapid virologic response

From: Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

No Age Sex HBD Regimen Liver disease HCV genotype Previous treatment experience Baseline HCV RNA (log10 IU/mL) Week 4 HCV RNA (log10 IU/mL) SVR12 status
2 41 Male HA SOF/LDV + RBV 24 W Non-cirrhotic 4 Naïve 6.94 2.24 SVR
5 31 Male HB SOF/LDV + RBV 24 W Non-cirrhotic 1 IFN-based 5.77 3.68 SVR
36 49 Male HA SOF/LDV + RBV 12 W Non-cirrhotic 1 Naïve 5.91 2.53 SVR
59 39 Male HB SOF/LDV + RBV 24 W Compensated cirrhosis 1 IFN-based 6.64 2.62 SVR
122 34 Female VWD SOF/LDV + RBV 12 W Non-cirrhotic 1 Naïve 6.21 2.12 SVR
130 32 Male HA SOF/LDV 12 W Non-cirrhotic 1 IFN-based 7.04 5.59 SVR
  1. HBD hereditary bleeding disorder, HA hemophilia A, HB hemophilia B, VWD Von Willebrand disease, SOF sofosbuvir, LDV ledipasvir, RBV ribavirin, IFN interferon, SVR sustained virologic response, W weeks